[0033a] In one aspect, the present disclosure provides for an ophthalmic composition comprising 0.5 % w/w to 1.0 % w/w of the HCl salt of Compound 1 of the formula:



Compound 1,

1.5 % w/w glycerin, 0.01 % w/w benzalkonium chloride, and 10 mM phosphate buffer in water, and having a pH of 6.

[0033b] In another aspect, the present disclosure provides for use of the ophthalmic composition as described herein in the manufacture of a medicament for treating allergic conjunctivitis.

[0033c] In another aspect, the present disclosure provides for use of the HCl salt of Compound 1 of the formula:



Compound 1,

in the manufacture of a medicament containing 1.5 % w/w glycerin, 0.01 % w/w benzalkonium chloride, and 10 mM phosphate buffer in water, and having a pH of 6 for treating allergic conjunctivitis.

[0034] Also provided are methods of using and preparing the compositions described herein.

[0035] These and other examples are described in more details in the text that follows.

WHAT IS CLAIMED IS:

1. An ophthalmic composition comprising 0.5 % w/w to 1.0 % w/w of the HCl salt of Compound 1 of the formula:



Compound 1,

1.5 % w/w glycerin, 0.01 % w/w benzalkonium chloride, and 10 mM phosphate buffer in water, and having a pH of 6.

2. The ophthalmic composition of claim 1 wherein the composition is stable for 6 months or more.

3. Use of the ophthalmic composition of claim 1 in the manufacture of a medicament for treating allergic conjunctivitis.

4. The use of claim 3, wherein the allergic conjunctivitis is chronic allergic conjunctivitis.

5. The use of claim 4, wherein the allergic conjunctivitis is acute allergic conjunctivitis.

6. The use of any one of claims 3-5, whereby one or more of redness, inflammation, swelling, discomfort, watery eye and itching of the eye, keratitis, corneal staining, conjunctival staining, or markers of inflammation of the eye is reduced or eliminated.

7. Use of the HCl salt of Compound 1 of the formula:



Compound 1,

in the manufacture of a medicament containing 1.5 % w/w/ glycerin, 0.01 % w/w/ benzalkonium chloride, and 10 mM phosphate buffer in water, and having a pH of 6 for treating allergic conjunctivitis.

8. The use of claim 7, wherein the HCl salt of Compound 1 is to be administered in an amount of 0.01 mg to 1 mg to an eye.

9. The use of claim 7 or 8, wherein the HCl salt of Compound 1 is to be administered once a day.

10. The use of claim 7 or 8, wherein the HCl salt of Compound 1 is to be administered twice a day.

11. The use of claim 7, wherein the allergic conjunctivitis is acute allergic conjunctivitis.

12. The use of claim 7, wherein the allergic conjunctivitis is chronic allergic conjunctivitis.

13. The use of claim 7, whereby one or more of redness, inflammation, swelling, eyelid congestion, watery eye and itching of the eye is reduced or eliminated.